Comparison of a new automated von Willebrand factor activity assay with an aggregation von Willebrand ristocetin cofactor activity assay for the diagnosis of von Willebrand disease
Authors:
- Katrien DevreeseKDKatrien Devreese
- 1 July 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 17 (5) , 353-358
Abstract
Von Willebrand disease (VWD) is caused by quantitative and/or qualitative defects of von Willebrand factor (VWF). The HemosIL von Willebrand Factor Activity assay, a new automated immunological test to measure VWF activity, was implemented on STAC and compared with the von Willebrand ristocetin cofactor activity (VWF:RCo) aggregation method. Imprecision and dilution studies were also performed. Within-run imprecision was 17.2% and between-run imprecision was 8.3% (coefficients of variation). Dilution studies showed a linearity between 12.5 and 100%. Passing and Bablok regression comparing the HemosIL von Willebrand Factor Activity assay and the aggregation method yielded a slope of 1.25 (95% confidence interval: 1.11-1.38) and intercept of -1.40 (95% confidence interval: -8.07 to 0.00). The correlation coefficient was 0.84 (95% confidence interval: 0.78-0.89). With a cut-off value of 50% for VWF activity, the assay has a sensitivity of 94.1% and a specificity of 92.8%, compared with the VWF:RCo aggregation assay with a cut-off value of 60% producing a sensitivity of 100.0% (specificity 87.6%). With a cut-off value of 60%, the HemosIL von Willebrand Factor Activity assay on STAC is a reliable assay for VWD. VWF:RCo or other functional testing is still required to confirm the diagnosis and for further classification of VWD.Keywords
This publication has 15 references indexed in Scilit:
- von Willebrand disease: laboratory aspects of diagnosis and treatmentHaemophilia, 2004
- The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors’ OrganizationHaemophilia, 2004
- von Willebrand Factor Collagen-Binding (Activity) Assay in the Diagnosis of von Willebrand Disease: A 15-Year JourneySeminars in Thrombosis and Hemostasis, 2002
- A Reliable von Willebrand Factor: Ristocetin Cofactor Enzyme-Linked Immunosorbent Assay to Differentiate between Type 1 and Type 2 von Willebrand DiseaseSeminars in Thrombosis and Hemostasis, 2002
- VON WILLEBRAND FACTORANDVON WILLEBRAND DISEASEReviews in Clinical and Experimental Hematology, 2001
- Congenital von Willebrand disease type 1: definition, phenotypes, clinical and laboratory assessmentBest Practice & Research Clinical Haematology, 2001
- A Reliable and Reproducible ELISA Method to Measure Ristocetin Cofactor Activity of von Willebrand FactorThrombosis and Haemostasis, 2000
- EFFECT OF MULTIMERIZATION OF HUMAN AND RECOMBINANT VON WILLEBRAND FACTOR ON PLATELET AGGREGATION, BINDING TO COLLAGEN AND BINDING OF COAGULATION FACTOR VIIIThrombosis Research, 1996
- Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric sizeBritish Journal of Haematology, 1989
- Assay of von willebrand factor in von willebrand's disease and hemophilia: Use of a macroscopic platelet aggregation testThrombosis Research, 1975